Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Glossary Glossary
The Body Covers: The 6th Conference on Retroviruses and Opportunistic Infections
Abstract No. 398: Treatment with d4T + ddI + Nelfinavir + Hydroxyurea for Early or Recent Primary HIV Infection

February 2, 1999

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Researchers from UCSF presented data from a study designed to assess the efficacy of a four-drug combination -- ddI/d4T/nelfinavir/hydroxyurea -- for patients with "early" HIV infection (defined as asymptomatic patients with a T-cell, or CD4, count above 500) or for recent HIV seroconverters (people who had been infected within 120 days of study entry).

Twenty patients with early HIV infection and sixteen patients with primary HIV infection were enrolled. All received the prescribed doses of d4T/ddI/nelfinavir, and took 500 mg of hydroxyurea twice-a-day. Baseline T-cell counts and viral loads were 745 cells and 10,300 copies/ml for those with early HIV infection, and 483 cells and 162,000 copies/ml for those with recent primary HIV infection. After 8 weeks of treatment, T-cell counts were 657 and 497 respectively, thus showing no statistically significant change. However, the CD4 cell percentage did increase from 33.8% to 39% in the early group, and from 26.3% to 37.4% in the seroconverter group. Ninety-five percent of subjects with early infection and 88% of those with recent primary infection had undetectable viral loads (below 50 copies). The study authors concluded that the four drug regimen was well-tolerated, and was a viable option for recently infected patients.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Abstract: Treatment with d4T + ddI + Nelfinavir + Hydroxyurea for Early or Recent Primary HIV Infection
Authored by: J. Kahn, R. Cone, F. Hecht, H. Sax, M. Chesney, B. Herndier, L. Reynolds, J.M. Ledeine, L. Dunkle, and M. Flepp

See Also
More Research on Primary (Acute) HIV Infection



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement